Yousif Capital Management LLC Reduces Holdings in Illumina, Inc. (NASDAQ:ILMN)

Yousif Capital Management LLC lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,940 shares of the life sciences company’s stock after selling 2,289 shares during the quarter. Yousif Capital Management LLC’s holdings in Illumina were worth $6,673,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ILMN. Massachusetts Financial Services Co. MA boosted its stake in shares of Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after purchasing an additional 631,294 shares during the period. Janus Henderson Group PLC increased its position in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after acquiring an additional 625,245 shares during the period. Iron Triangle Partners LP bought a new stake in shares of Illumina during the third quarter valued at approximately $57,380,000. FMR LLC grew its stake in Illumina by 127.3% in the third quarter. FMR LLC now owns 767,294 shares of the life sciences company’s stock worth $100,063,000 after purchasing an additional 429,723 shares in the last quarter. Finally, PointState Capital LP purchased a new position in Illumina during the 3rd quarter worth $39,420,000. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of recent research reports. Robert W. Baird increased their price target on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group boosted their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada increased their target price on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $164.84.

Illumina Stock Performance

Shares of ILMN opened at $122.80 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a 50-day moving average of $137.80 and a two-hundred day moving average of $135.42. The stock has a market cap of $19.48 billion, a P/E ratio of -12.33 and a beta of 1.10. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. As a group, research analysts predict that Illumina, Inc. will post 4.13 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.